Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $7.73B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2026 · Mkt cap
Decision snapshot: ALKS stock price vs QRVO: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at QRVO's multiple
Needs QRVO P/E.
Implied fair value · at ALKS's multiple
Needs ALKS P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: ALKS FY 2025 (ended Dec 31, 2025) · QRVO FY 2026 (ended Mar 28, 2026). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 96% equity / 4% debt · EV / Revenue 5.19x · EV / EBITDA 23.76x
Capital structure 85% equity / 15% debt · EV / Revenue 2.55x · EV / EBITDA 11.63x
QRVO carries the larger enterprise value at $9.38B against $7.66B; QRVO trades on the lower EV / Revenue multiple (2.55x vs 5.19x); QRVO on the lower EV / EBITDA (11.63x vs 23.76x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Alkermes plc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Qorvo, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.17x
0.46x
Net debt / EBITDA
Leverage against operating earnings
-0.22x
0.41x
Cash and equivalents
Liquid reserves on the balance sheet
$388.57M
$1.22B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Jazz Pharmaceuticals plc
ALKS vs JAZZ
SUPERNUS PHARMACEUTICALS, INC.
ALKS vs SUPN
Amneal Pharmaceuticals, Inc.
ALKS vs AMRX
SKYWORKS SOLUTIONS, INC.
ALKS vs SWKS
Broadcom Inc.
ALKS vs AVGO
Marvell Technology, Inc.
ALKS vs MRVL
ON SEMICONDUCTOR CORP
ALKS vs ON
NXP Semiconductors N.V.
ALKS vs NXPI
TEXAS INSTRUMENTS INC
ALKS vs TXN
$317.13M
$1.55B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
